Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Cilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.
- Mechanism
- Curator reviewed
Cilansetron is a potent and selective 5-HT3 receptor antagonist. 5-HT3 receptors are nonselective cation channels that are extensively distributed on enteric neurons in the human gastrointestinal tract, as well as other peripheral and central locations. Activation of these channels and the resulting neuronal depolarization affect the regulation of visceral pain, colonic transit and gastrointestinal secretions, processes that relate to the pathophysiology of irritable bowel syndrome (IBS). 5-HT3 receptor antagonists such as cilansetron inhibit activation of non-selective cation channels which results in the modulation of the enteric nervous system.
- Primary indication
- For the treatment of symptoms associated with irritable bowel syndrome.Curator reviewed
- Formula / weight
- C20H21N3O · 319.4002 g/mol (avg)
- Code names
- KC-9946
Resolves to
NCNFDKWULDWJDS-OAHLLOKOSA-NSMILESCC1=NC=CN1C[C@H]1CCC2=C(C3=CC=CC4=C3N2CCC4)C1=OWhat you can answer from here — as of March 06, 2025
Which drugs share a target with Cilansetron, and which of those have an active Phase 3 trial?